FLAGSHIP PIONEERING
55 Cambridge ParkwayCambridge, MA 02142-1234
Firm Size
- Assets Under Management (AUM):$14.1 Billion
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Healthcare
Description
Flagship Pioneering, Inc. is a renowned innovation company based in Cambridge, Massachusetts. Founded in 2000, the firm specializes in conceiving, creating, and operating life sciences companies to pioneer and transform technological advancements across multiple industries. The company's unique approach involves utilizing its proprietary innovation foundry, where it generates and nurtures disruptive ideas and concepts. Flagship Pioneering has successfully launched and developed numerous groundbreaking companies that have made significant contributions to the fields of healthcare, agriculture, sustainability, and more. Its portfolio includes industry-leading companies such as Moderna, Indigo Agriculture, Axcella Health, and Sana Biotechnology. Through its expertise and resources, the company provides support to its companies in all facets of their development, including scientific research, business strategy, operational execution, fundraising, and commercialization efforts. Flagship Pioneering's team of experienced professionals, including scientists, entrepreneurs, and industry experts, work collaboratively to drive innovation and bring transformative technologies to market. The company's headquarters in Cambridge, Massachusetts, serves as the hub for its operations and supports its growing network of entrepreneurs, innovators, and strategic partners. With its commitment to pushing the boundaries of science and technology, Flagship Pioneering continues to play a key role in pioneering groundbreaking solutions to address the world's most pressing challenges.Latest News
Powered by
Jun 13, 2024: InduPro Announces $85 Million Series A Financing, Appoints Prakash Raman, Ph.D. as CEO to Advance Next-Generation, Proximity-Based Protein Therapeutics for the Treatment of Cancer and Autoimmune Disea
Jun 12, 2024: Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
Flagship Pioneering and ProFound™ Therapeutics , a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a multitude of diseases, today announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity. The collaboration is the first initiated under Flagship's Pioneering Medicines strategic partnership with Pfizer Inc. announced in July 2023 .
May 09, 2024: Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management
Apr 08, 2024: Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director.
Mar 19, 2024: Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company 's prestigious list of the World's Most Innovative Companies of 2024, ranking as the #3 most innovative company in North America . This is the third consecutive year Flagship has been named to the list, moving up two spots since 2023.
Feb 27, 2024: J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board
J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board. Mr. Epstein was CEO of Seagen before closing its sale to Pfizer in December 2023 . David previously served as Executive Partner at Flagship Pioneering as well as CEO of Novartis Pharmaceuticals. His 30 years of industry experience includes drug development, deal making, venture investing, commercialization, and leadership experience on a global scale.
Jan 16, 2024: Valo Health Announces Changes to its Board of Directors and Leadership Team
Valo Health, Inc ("Valo") , a technology company focused on utilizing large scale data and artificial intelligence ("AI") driven computation to discover and develop therapeutics, today announced the appointment of Christian Schade as the newly-created role of Executive Chairman of the Board of Directors and Graeme Bell as interim CEO, effective immediately.
Jan 09, 2024: DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING
Flagship Pioneering, the bioplatform innovation company, and Indigo Ag , an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag , effective February 1, 2024 . Banks will also continue as an Indigo board member, a role he has held since July 2022 . Indigo also announced the appointments of Nader Bekhouche (Investment Corporation of Dubai ) and Noubar Afeyan (Flagship Pioneering) to its Board of Directors. As a follow up to the company's initial financing announcement in September 2023 , Indigo also announced the final close of its financing round at an expanded raise of nearly $270 million .
Jan 08, 2024: Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
Flagship Pioneering, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine.
Jan 08, 2024: Flagship Pioneering Debuts Enabling Technologies Initiative
Flagship Pioneering, the bioplatform innovation company, today announced the formation of a new strategic initiative to foster enabling technologies for the life sciences and biotech sectors. The initiative will work with partners and across Flagship and its ecosystem of companies to accelerate the development of new therapeutic modalities by enabling and powering advanced technologies. Foundational to the new initiative is the formation and expansion of new partnerships, including with Thermo Fisher Scientific and announced today with Samsung C&T.
Nov 28, 2023: Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders
Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.
Nov 07, 2023: Flagship Pioneering Expands into Asia-Pacific Region, with Regional Hub in Singapore
Flagship Pioneering, the bioplatform innovation company, today announced its expansion into the Asia-Pacific region, with the opening of a regional hub in Singapore . This follows the company's expansion into the UK earlier this year. André Andonian has joined Flagship as Chair of Asia Pacific and Senior Advisor to lead Flagship's presence in the region with a focus on furthering the global reach and impact of Flagship and its companies. He will also serve as an advisor on broader global strategy, regional investor engagement, and institutional development.
Nov 01, 2023: Flagship Pioneering Launches Pioneering Intelligence
Flagship Pioneering today launched Pioneering Intelligence, an initiative of Flagship Pioneering harnessing artificial intelligence (AI) to accelerate innovation in the life sciences and beyond. Flagship marked the official launch of Pioneering Intelligence with an AI Summit that drew tech and life sciences leaders from around the globe for a day long series of talks. Initiated in 2021, Pioneering Intelligence will augment the capabilities of Flagship companies, drive AI and machine learning (ML) innovation, and originate new platform companies built on AI advances.
Oct 19, 2023: Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines
Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the design and deployment of fully programmable medicines to transform patient care. Sail harnesses the power of first-in-category programmable payloads of Endless RNA ™ (eRNA), first-in-category programmable nanoparticles, and emerging, proprietary AI technologies, to unlock the comprehensive programming of medicines for the first time. Guillaume Pfefer , Ph.D., MBA, who is also CEO-Partner at Flagship Pioneering, will become Sail's CEO and board member, while John Mendlein , Ph.D., who also serves as Executive Partner, Flagship Pioneering, will become the company's Executive Chairman.
Oct 02, 2023: Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics
Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore , M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023 .